Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression
2021 · Frontiers in Immunology · 10 citations
https://doi.org/10.3389/fimmu.2021.610149
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
4
Papers
87
Citations
2
h-index
2
i10-index
Dingyong Wu is an academic researcher from Zhongshan Hospital. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Cancer Genomics and Diagnostics & Epigenetics and DNA Methylation. The author has an h-index of 2, co-authored 4 publications.
https://doi.org/10.3389/fimmu.2021.610149
https://doi.org/10.1186/s41065-025-00430-7
Click to start Chat